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Conformational Changes in Voltage-Sensing Domains: Concerted Simula-
tion and Scattering Studies
Douglas J. Tobias.
Chemistry, University California, Irvine, Irvine, CA, USA.
Electrical signals in excitable tissues such as nerves and muscles are generated
by the synchronized opening and closing of ion channels in cell membranes,
which generate transient transmembrane gradients in the concentrations of
sodium and potassium ions. These channels open and close in response to local
changes in transmembrane potential as the signal propagates, and it is well
established that their voltage sensitivity is conferred by charged structural ele-
ments, referred to as voltage-sensing domains. The details of how conforma-
tional changes in the voltage-sensing domains lead to opening/closing of the
ion-conducting pores of the channels are still being worked out. Crystal struc-
tures of the open states of voltage-gated potassium channels are available, but
the structure of the closed/resting state has not been determined to high resolu-
tion experimentally. In this talk I will report our efforts to generate a model of
the resting state of the archaeal KvAP potassium channel based on atomistic
molecular dynamics (MD) simulations in explicit membrane environments,
with restraints derived from experimental functional data. I will also present re-
sults from simulation studies of an isolated voltage-sensing domain in a hydrat-
ed membrane, which include validation by neutron diffraction measurements,
and direct observations of elementary gating charge displacement events during
a 30-microsecond MD simulation under applied transmembrane potential.
Finally, I will discuss prospects for and present preliminary results on using
x-ray and neutron interferometry measurements, carried out by our collabora-
tors, to validate and refine simulation-based models of the resting state and the
voltage-sensing mechanism.
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Tricking Out the Toolbox: Use of Genetic Code Expansion for the Study of
Ion Channels
Chris Ahern.
Molecular Physiology and Biophysics, University of Iowa, Iowa City, IA,
USA.
The application of nonsense suppression strategies to membrane proteins has
great potential for the study and manipulation of ion channels and receptors.
The technique relies on the incorporation of a stop codon that is subsequently
‘suppressed’ by an orthogonal misacylated tRNA. Ion channels in particular are
especially amenable to these approaches due to the built-in signal gain from the
high conductance of recorded ions. On one end of the scale of possibility,
‘small mutagenesis’ provides the means for single atom replacement within
an amino acid or sub-atomic redistribution of pi electrons of aromatic side-
chains. Such approaches provide an atomic resolution functional correlates to
match high-resolution structural data, and have been key in decoding the inter-
action energetics of ligands, therapeutics, backbone contributions, salt-bridges
and H-bonds in gating of voltage- and ligand-gated channels and receptors.
More unconventional side-chains, such as light activated cross-linkers, hold
promise for their ability to characterize transient noncovalent protein contacts.
Lastly, encoded amino acid fluorophores, while highly valued, have been tech-
nically resistant to ion channel application and largely remain on the experi-
mental fringe. Data will be presented on the use of genetic code expansion
as a tool to reveal the basis for inactivation mechanisms employed by
voltage-gated sodium and potassium channels.
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Small Molecule Modulation of Voltage-Gated Ion Channels
Heike Wulff1, Vladimir Yarov-Yarovoy2.
1Pharmacology, University of California, Davis, Davis, CA, USA,
2Physiology and Membrane Biology, University of California, Davis, Davis,
CA, USA.
Pharmacological modulation of voltage-gated-like ion channels offers tremen-
dous opportunities for the discovery of new drugs for neurological, cardiovas-
cular and metabolic disorders, as well as for immunosuppression and cancer.
However, in contrast to other therapeutic targets such as protein kinases,
voltage-gated ion channels have not been popular with medicinal chemists in
the pharmaceutical industry. One reason for this unpopularity is the absence
of co-crystals of medically relevant channels with drug molecules bound, a pre-
requisite for structure based drug design. To address this challenge, molecular
modeling, which recently made significant advances due to improved compu-
tational methods, and the availability of more high-resolution ion channel struc-
tures, is increasingly being used to interpret the results of mutational andelectrophysiological experiments in structural terms. Using the Kv1.3 blocker
PAP-1 and several KCa2/3 channel modulators such as TRAM-34, NS8593,
and nifedipine as examples we here demonstrate that small molecule drugs
can ‘‘snuggle’’ into every available nook and cranny of voltage-gated ion chan-
nels: the central cavity, the side-pockets between the pore-domain and voltage-
sensor, the S5-S6 interface or the lateral fenestrations. We will further discuss
the recent design of the KCa3.1 selective positive gating modulator SKA-121
(5-methylnaphtho[2,1-d]oxazol-2-amine), a compound that binds at the inter-
face of the calmodulin N-lobe and the calmodulin binding domain of
KCa3.1. Overall these examples illustrate that voltage-gated ion channels are
highly accessible to small molecule drugs and that virtually any domain of
these large, multi-subunit proteins can be targeted for the design of channel
subtype-specific drugs, a major challenge remaining in the ion channel field.
Supported by RO1 GM076063 (to H.W.) and UC Davis startup (to V.Y.).
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Calcium Channel Engineering
Henry M. Colecraft.
Physiology and Cellular Biophysics, Columbia University, New York,
NY, USA.
High-voltage-activated calcium (CaV) channels convert electrical signals into
Ca2þ ion influx to trigger biological responses in excitable cells. CaV channel
dysfunction underlies many cardiovascular and neurological diseases, from
cardiac arrhythmias to autism. Modulation of CaV channels by intracellular
signaling proteins, Ca2þ ions and various small molecules is a powerful method
to regulate physiology and is therapeutic for myriad disease conditions. I will
discuss CaV channel engineering approaches that we have used to gain insights
into the structure-function mechanisms of these vital proteins, to probe their
physiological roles, and to develop novel genetically-encoded molecules that
modulate their activity.Platform: Calcium Signaling
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Decreased Polycystin 2 Expression Alters Calcium-Contraction Coupling
and Changes Beta-Adrenergic Signaling Pathways
Ivana Y. Kuo1, Andrea T. Kwaczala2, Lily Nguyen3, Stuart G. Campbell2,
Barbara E. Ehrlich1.
1Pharmacology, Yale University, New Haven, CT, USA, 2Biomedical
Engineering, Yale University, New Haven, CT, USA, 3Cardiology, Yale
University, New Haven, CT, USA.
Cardiac disorders are the main cause of mortality in autosomal dominant poly-
cystic kidney disease (ADPKD). However, how mutated polycystins predis-
pose ADPKD patients to cardiac pathologies before development of renal
dysfunction is unknown. We investigate the effect of decreased polycystin 2
(PC2) levels, a calcium channel that interacts with the ryanodine receptor, on
myocardial function. We hypothesize that heterozygous PC2 mice (Pkd2þ/)
undergo cardiac remodeling due to changes in calcium handling, separate to
renal complications. We found that Pkd2þ/ cardiomyocytes have altered cal-
cium handling, independent of desensitized calcium-contraction coupling.
Paradoxically, in Pkd2þ/ mice, PKA phosphorylation of phospholamban
was decreased, whereas PKA phosphorylation of troponin I was increased, ex-
plaining the decoupling between calcium signaling and contractility. In silico
modeling supported this relationship. Echocardiography measurements showed
that Pkd2þ/ mice have increased left ventricular ejection fraction after stim-
ulation with isoproterenol (ISO), a b-adrenergic receptor (bAR) agonist.
Blockers of bAR-1 and 2 inhibited the ISO response in Pkd2þ/ mice, sug-
gesting that the dephosphorylated state of phospholamban is primarily by
bAR-2 signaling. Importantly, the Pkd2þ/ mice were normotensive and
had no evidence of renal cysts. Our results showed that decreased PC2 levels
shifted the bAR pathway balance and changed expression of calcium handling
proteins, which resulted in altered cardiac contractility. We propose that PC2
levels in the heart directly contribute to cardiac remodeling in ADPKD patients
in the absence of renal dysfunction.
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In vivo Reconstitution of the Mitochondrial Uniporter
Erika Kovacs-Bogdan1, Yasemin Sancak1, Kimberli J. Kamer1,
Molly Plovanich1, Ashwini Jambhekar1, Robert J. Huber2, Michael A. Myre2,
Michael D. Blower1, Vamsi K. Mootha1.
1Molecular Biology, Massachusetts General Hospital, Boston, MA, USA,
2Department of Neurology, Massachusetts General Hospital, Boston,
MA, USA.
The mitochondrial uniporter is a highly selective calcium channel present
broadly in eukaryotes, but absent in Saccharomyces cerevisiae. Therefore,
